Patents by Inventor Ronald Charles Bernotas

Ronald Charles Bernotas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS
    Publication number: 20120010205
    Abstract: Disclosed are quinoline esters of Formula (I): which are useful as Liver X receptors (LXR) modulators. Pharmaceutical compositions containing quinoline esters of Formula (I) and the use of quinoline esters of Formula (I) in the safe treatment of various skin disorders are also disclosed. Methods for preparing and using quinoline esters are further described.
    Type: Application
    Filed: July 7, 2011
    Publication date: January 12, 2012
    Applicant: Wyeth LLC
    Inventors: Ronald Charles Bernotas, Robert Singhaus, Sunil Nagpal, Catherine Thompson
  • Imidazo [1,2-A] Pyridine Compounds
    Publication number: 20110112135
    Abstract: This invention relates generally to imidazo[1,2-a]pyridine-based modulators of Liver X receptors (LXRs) having formula (I) and related methods: wherein R2 is C6-C10 aryl or heteroaryl including 5-10 atoms, each of which is: (i) substituted with 1 R7, and (ii) optionally substituted with from 1-5 Re; and R1, R3, R4, R5, R6, R7, and Re are defined herein.
    Type: Application
    Filed: December 19, 2008
    Publication date: May 12, 2011
    Inventors: Robert Ray Singhaus, JR., Ronald Charles Bernotas, Jay Edward Wrobel, Robert John Steffan, Edward Martin Matelan
  • Benzimidazole Compounds
    Publication number: 20110034526
    Abstract: This invention relates generally to benzimidazole-based modulators of Liver X receptors (LXRs) having formula (I) and related methods: wherein R2 is C6-C10 aryl or heteroaryl including 5-10 atoms, each of which is: (i) substituted with 1 R7, and (ii) optionally substituted with from 1-5 Re; and R1, R3, R4, R5, R6, R7, and Re are defined herein.
    Type: Application
    Filed: December 19, 2008
    Publication date: February 10, 2011
    Applicant: Wyeth LLC
    Inventors: Ronald Charles Bernotas, Jeremy Mark Travins, Jay Edward Wrobel, David Harry Kaufman
  • Quinazoline Compounds
    Publication number: 20100273816
    Abstract: Disclosed are quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, W, W1, W2, W3, A, Ra, Ra?, Rb, Rb?, Rc, Rd, Rd?, Re, Rf, Rg, Rh, Ri Rj, Rk, Rm, Rn, Ro, Rp, Rq, and n, can be, independently, as defined anywhere herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
    Type: Application
    Filed: May 15, 2008
    Publication date: October 28, 2010
    Inventors: Ronald Charles Bernotas, John William Ullrich, Jeremy Mark Travins, Jay Edward Wrobel, Rayomand Jal Unwalla
  • Polar Quinazolines
    Publication number: 20100184786
    Abstract: Disclosed are polar quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): in which, R1, R2, R3, R4, R5, R6, R22, R23, R24, R25, R26, R27, R28, R29, W, W1, W2, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, and n can be as defined anywhere herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
    Type: Application
    Filed: November 19, 2009
    Publication date: July 22, 2010
    Applicant: Wyeth LLC
    Inventors: Jeremy Mark Travins, Ronald Charles Bernotas, Jay Edward Wrobel, David Harry Kaufman, Baihua Hu, James Winfield Jetter, David John O'Neill, Charles William Mann
  • Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7723329
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: May 25, 2010
    Assignee: Wyeth LLC
    Inventors: Hassan Mahmoud Elokdah, Alexander Alexei Greenfield, Kevin Liu, Robert Emmett McDevitt, Geraldine Ruth McFarlane, Cristina Grosanu, Jennifer Rebecca Lo, Yanfang Li, Albert Jean Robichaud, Ronald Charles Bernotas
  • Oxazolidine derivatives as PR modulators
    Patent number: 7649007
    Abstract: Compounds of the following structure are described: wherein R1-R6, m, V, W, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: January 19, 2010
    Assignee: Wyeth LLC
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Oxazolidone derivatives as PR modulators
    Patent number: 7618990
    Abstract: Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: November 17, 2009
    Assignee: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Tricyclic oxazolidone derivatives useful as PR modulators
    Patent number: 7618989
    Abstract: Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: November 17, 2009
    Assignee: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 7608717
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: October 27, 2009
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Ronald Charles Bernotas
  • HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20090253711
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: June 12, 2009
    Publication date: October 8, 2009
    Applicant: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
  • 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7589108
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: September 29, 2005
    Date of Patent: September 15, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek
  • 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7585873
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: September 8, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler Adam Antane
  • Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7585876
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: September 8, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Derek Cecil Cole, William Joseph Lennox
  • Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7576087
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: August 18, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan
  • Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7560470
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: July 14, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
  • Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 7544701
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: June 9, 2009
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Ronald Charles Bernotas
  • Oxazinan-2-one derivatives useful as PR modulators
    Patent number: 7538107
    Abstract: Compounds of the following structure are described: wherein R1-R6, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: May 26, 2009
    Assignee: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Jr., Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Quinoline Acids
    Publication number: 20090069373
    Abstract: This invention relates generally to quinoline-based modulators of Liver X receptors (LXRs) and related methods.
    Type: Application
    Filed: February 28, 2008
    Publication date: March 12, 2009
    Applicant: Wyeth
    Inventors: Jay E. Wrobel, Baihua Hu, Michael David Collini, James Winfield Jetter, Ronald Charles Bernotas, David Harry Kaufman, Robert Ray Singhaus, JR., John William Ullrich, Robert Lester Morris, Rayomand J. Unwalla
  • Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands
    Patent number: 7498327
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: March 3, 2009
    Assignee: Wyeth
    Inventors: Youchu Wang, Chia-Cheng Shaw, Ronald Charles Bernotas, Chung-Chiee Paul Wang, Ping Cai, Zhi Wang